Piperidine

Piperidine

SCHEMBL1793471

C1CCNCC1.NC(=O)O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.56
ACHE P22303 1/20 0.44
KDM4E B2RXH2 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
CYP2D6 P10635 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
CXCR4 P61073 1/20 0.39
CA2 P00918 1/20 0.39
CHKA P35790 1/20 0.39
TSHR P16473 2/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Azepane SCHEMBL29776406 1.00 ALDH1A1 (0.56) ALDH1A1ACHEKDM4EKMT2AMAPT
Piperidine SCHEMBL10778074 1.00 ALDH1A1 (0.56) ALDH1A1ACHEKDM4EKMT2AMAPT
Azepane SCHEMBL9998550 1.00 ALDH1A1 (0.56) ALDH1A1ACHEKDM4EKMT2AMAPT
Piperidine SCHEMBL8761997 1.00 ALDH1A1 (0.56) ALDH1A1ACHEKDM4EKMT2AMAPT
Piperidine SCHEMBL3873742 0.97 ALDH1A1 (0.53) ALDH1A1ACHEKDM4EKMT2AMAPT
Azepane SCHEMBL20740114 0.97 ALDH1A1 (0.53) ALDH1A1ACHEKDM4EKMT2AMAPT
Pyrrolidine SCHEMBL1793163 0.97
Pyrrolidine SCHEMBL15387295 0.97 ALDH1A1 (0.50) ALDH1A1ACHEKDM4EKMT2AMAPT
Benzene SCHEMBL28071205 0.91 ALDH1A1 (0.44) ALDH1A1ACHEKDM4EKMT2AMAPT
Piperidine SCHEMBL3283269 0.90 ALDH1A1 (0.60) ALDH1A1KDM4EKMT2AMAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1189061-B1 Multifunctional erythrocyte reagent containing carbamates and uses IMMUNOTECH SA (FR) 2009-12-02 EP claimed
CN-1894173-A Preparation of 18-fluoro-labeled aromatic amino acids UNIV EBERHARD KARLS (DE) 2007-01-10 CN claimed
US-20020115118-A1 Multi-functional reagent for erythrocytes IMMUNOTECH (FR) 2002-08-22 US claimed
US-12590123-B2 Compounds and methods for treating cancer, viral infections, and allergic conditions WASHINGTON UNIVERSITY (US) 2026-03-31 US disclosed
EP-3870285-B1 SYNTHESIS OF ESUBERAPROST PRODRUGS UNITED THERAPEUTICS CORP (US) 2025-06-18 EP disclosed
US-20250154181-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2025-05-15 US disclosed
US-12173021-B2 Treprostinil prodrugs UNITED THERAPEUTICS CORPORATION (US) 2024-12-24 US disclosed
US-12162853-B2 Synthesis of esuberaprost prodrugs UNITED THERAPEUTICS CORPORATION (US) 2024-12-10 US disclosed
US-20240327352-A1 NOVEL PROCESS FOR THE PREPARATION OF 1-(2-{4-[(4-CARBAMOYLPIPERIDIN-1-YL)METHYL]- N-METHYLBENZAMIDO}ETHYL)PIPERIDIN-4-YL N-({1,1'-BIPHENYL}-2-YL)CARBAMATE MSN LABORATORIES PRIVATE LTD, R&D CENTER (IN) 2024-10-03 US disclosed
CN-118613156-A Non-transgenic sunflower plants with increased tolerance to herbicides 巴斯夫农业种子解决方案美国有限责任公司 2024-09-06 CN disclosed
US-12049466-B2 Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-30 US disclosed
CN-1309184-A Operation of enzymatic vitality of protoporphyrin primary oxidase in eukaryote NOVARTIS AG (CH) 2001-08-22 CN disclosed
CN-1309638-A N-substituted naphthamides as neurokinin receptor antagonists ASTRAZENECA AB (SE) 2001-08-22 CN disclosed
US-20010008892-A1 Retroviral protease inhibiting compounds CHEN XIAOQI (US) 2001-07-19 US disclosed
EP-1077977-A1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 2001-02-28 EP disclosed
WO-1999059994-A1 RETROVIRAL PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1999-11-25 WO disclosed
EP-0944730-A1 METHOD FOR PRODUCTION OF D-PROLINE DERIVATIVES LONZA A.G. (CH) 1999-09-29 EP disclosed
WO-1998027222-A1 METHOD FOR PRODUCTION OF D-PROLINE DERIVATIVES LONZA AG (CH) 1998-06-25 WO disclosed
CN-1150820-A Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotes CIBA GEIGY AG (CH) 1997-05-28 CN disclosed
EP-0001402-A1 Substituted piperidinhydroxycarboxylic acid amides, their preparation and their application as light stabilisers HOECHST AKTIENGESELLSCHAFT (DE) 1979-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154181-A1 TREPROSTINIL PRODRUGS TYMP, TK1, DCTPP1 ALDH1A1 758/4885ACHE 2213/4885KDM4E 3961/4885
US-12590123-B2 Compounds and methods for treating cancer, viral infections, and allergic conditions TMPRSS2, TMPRSS4, F2RL3 ALDH1A1 2827/4885ACHE 4388/4885KDM4E 1739/4885
US-12162853-B2 Synthesis of esuberaprost prodrugs DCPS, DNPEP, NPEPPS ALDH1A1 1494/4885ACHE 1047/4885KDM4E 3376/4885
US-20240327352-A1 NOVEL PROCESS FOR THE PREPARATION OF 1-(2-{4-[(4-CARBAMOYLPIPERIDIN-1-YL)METHYL]- N-METHYLBENZAMIDO}ETHYL)PIPERIDIN-4-YL N-({1,1'-BIPHENYL}-2-YL)CARBAMATE CYP4B1, CYP1B1, KDM4B ALDH1A1 250/4885ACHE 137/4885KDM4E 15/4885
US-12049466-B2 Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors USP30, UCHL1, ADRM1 ALDH1A1 1330/4885ACHE 1432/4885KDM4E 2992/4885
US-12173021-B2 Treprostinil prodrugs TYMP, TK1, DCTPP1 ALDH1A1 758/4885ACHE 2213/4885KDM4E 3961/4885
US-20010008892-A1 Retroviral protease inhibiting compounds PREP, DNPEP, SERPINB1 ALDH1A1 4014/4885ACHE 2682/4885KDM4E 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.